Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 3;17(6):5094–5102. doi: 10.3892/ol.2019.10208

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Zhu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — Plasma IL-35 concentration and clinicopathological characteristics of patients with PCA. (A) Plasma IL-35 concentration among patients with either PCA or BPH and the HC group. *P<0.05 and ****P<0.0001. (B) Plasma IL-35 concentration among of patients with different Gleason scores. *P<0.05 and ***P<0.001. (C) Plasma IL-35 concentration among of patients with different Tumor-Node-Metastasis stages. ***P<0.001. (D) Plasma IL-35 concentration of patients with or without lymph node metastasis. ****P<0.0001. (E) Plasma IL-35 concentration of patients with or without distant metastasis. ****P<0.0001. (F) Overall survival rate of patients with PCA with a high or low plasma IL-35 concentration. P=0.0071. IL-35, interleukin-35; PCA, prostate cancer; BPH, benign prostatic hyperplasia; HC; healthy control; N0, negative for lymph node metastasis; N1, positive for lymph node metastasis; M0, negative for distant metastasis; M1, positive for distant metastasis.